

Transition to the eCTD

Trying to find the right road

Points to be Covered

- Description of GSK's implementation plan for the eCTD
 - Activity plan
 - Issues that emerge
- Submitting CTDs electronically (absent a Agency review tool)
- eIND as the preferred path for adoption of the eCTD



eCTD Implementation

 Team formed with representation from USRA, UK, Canada, Germany and Belgium

- Impact analysis of the eCTD
- Develop prototype eCTD
- Interface with the CTD Implementation team
- Points of contact with external groups
 - PhRMA
 - EFPIA



Impact Analysis

- Followed on the work already done by the CTD implementation team
- Senior Management endorsement of transition to CTD
- Impact Analysis
 - Authoring (document granularity)
 - Publishing Table of Content builder
 - Document Management considerations for meta-data



Development of a Prototype

- Need to evaluate against representative document/file type rather than "placeholders"
- Need to move beyond the "simple" exercise of creating a table of contents and assess issues relating
 - Cross-references
 - Cross-document linking
 - Dossier navigation
 - Query ability
- Assess the impact of the transition to the eCTD against the existing functionality in eNDA, aMAA that we had prepared



Development of a Prototype (2)

- Retrofit of a submitted NDA/MAA into CTD
 - Basis for decisions around document granularity, section numbering, cross-reference approach
 - Exercise help drive internal review of draft eCTD specification
 - Test files for the evaluation of tools
 - Intended for internal training
 - Intended for discussion with Agency reviewers



Key Considerations for the eCTD

- Potential changes in cross-referencing strategies
 - Chem Abstracts vs Vancouver convention
 - Link to files (XML) versus link to pages (PDF)
- Need to consider the appropriate level of granularity for files
 - Clinical Summary (2.7) can be broken down into 6 files (for each major subsection)
 - Non-Clinical Summary (2.6) can be broken down into 7 files (for each major sub-section)
 - Quality Summary (2.3) can be either provided as one file or as a collection of files (for each major sub-section)
 - Clinical Report is viewed as being comprised of 35 elements/files
- The approach should anticipate life-cycle maintenance and the need to modify or update files post-approval



Some key issues along the way

- Module 1 DTD undergoing change
- Available tools limited by the present (draft) state of the specifications
- Review tool(s) that will be used by Regulatory Authorities
- Interface with Regulatory reviewers what are the expectations
- "Recommended but not required" in US and Canada
- If we create an eCTD, will the reviewers be ready for it?
- Managing present demands to supply electronic submissions (in CTD format) to the FDA



Electronic submission of CTDs (Interim)

- FDA Guidance document (Sep 2001) allowed for the electronic submission of CTD using NDA/BLA file folder structures
- Transitional model presents "interesting" challenges for dossier publishing
- Different electronic submissions for each region
- Despite limitations, The Interim solution may represent a viable bridging strategy



Module	Description	Folder
Module 1	FDA form 356h	NDA Root Directory
	Cover Letter	
Module 1	Comprehensive table of contents	NDA Root Directory
Module 1	Administrative documents	Other
	 Patent Information 	
	Patent Certification	
	 Debarrment Certification 	
	 Field Copy Certification 	
	 User Fee Cover Sheet 	
	Financial disclosure information	
	 Foreign Marketing Experience 	
	 Risk Management Plan 	

GlaxoSmithKline

Module	Description	Folder
Module 1	 Prescribing information Proposed labeling Labeling History Package Labeling Container Labeling Annotated Labeling 	Labeling



Module	Description	Folder
Module 2	 2.1 Table Of Contents 2.2 Introduction 2.3 Overall Quality Summary 2.4 Non-Clinical Overview 2.5 Clinical Overview 2.6 Non-Clinical Summary 2.7 Clinical Summary hypertext links will be provided to narratives, study synopses, and datasets in clinical study reports integrated datasets in Module 5 	Summary



Proposed Folder Structure

Module	Description	Folder
Module 3	Quality	CMC
Module 4	Non-Clinical Study Reports	PathTox



Module	Description	Folder
Module 5	5.1 Table of Contents	Clinstat
	5.2 Tabular listing of studies	
Module 5	5.3 Clinical Study Reports	
	5.3.1 Report of Biopharmaceutic Studies	HPBIO
	5.3.2 Reports of Studies Pertinent to Pharmacokinetics Using Human Biomaterials	ΗΡΒΙΟ
	5.3.3 Reports of Human Pharmaokinetic (PK) Studies	НРВІО
	5.3.4 Reports of Human Pharmacodynamic (PD) Studies	Clinstat



Module	Description	Folder
Module 5	5.3.5 Reports of Efficacy and Safety Studies	Clinstat
Module 5	 5.3.5.3 Reports of Analyses of Data from More Than One Study, Including Any Formal Integrated Analyses, Meta-analyses, and Bridging Analyses Tables and listing that support the Clinical Safety Summary will be included. Integrated datasets will also be included in the CRT folder 	Clinstat



Module	Description	Folder
Module 5	5.3.6 Reports of Post-Marketing Experience	Clinstat
Module 5	5.3.7 Case Report Forms and Individual Patient Listings	
	 Datasets (individual study datasets and integrated safety datasets 	CRT
	• CRFs	CRF
Module 5	Literature References	Clinstat/Pubs



Will the eCTD be ready for Prime Time?

- Concept needs to be translated into acceptable specifications
- No perceived loss in functionality (e.g., hypertext links)?
- FDA developing review tool for eCTD (Version 1: Spring 2003)
- Impact of different viewers adopted in different regions
- Will the transition to eCTD facilitate or impair ease of communication between Regulatory reviewers and internal sponsor staff (How did you get to that document?)
- Will the eCTD truly handle maintenance submission?
- Linkage between IND and NDA?



eIND as Transition to eCTD

- Possible resistance to change to the eCTD for NDA
 - Not required in the US
 - Feature comparison vs. eNDA
- eIND provides a stronger business case for the eCTD
 - Dynamic information exchanges
 - Stronger case for the need to re-use and re-present information
- View of the eIND as building the CTD marketing application over time




Case for the eIND

- The management of an "infobase" of product information during development
 - How is this information actively shared within the company?
 - How does the FDA track issues?
- The information can be re-used many times or requires minor modification
- Most of the information will be "resubmitted" as an NDA or BLA – How/what is the extent of rework?



IND Life Cycle

IND Life Cycle





CDER CTOC Prototype for the eIND

- Introduced for consideration in a public meeting in January 2001
- Built around XML-based cumulative table of contents
- Meta data are associated with each file that is submitted
 - Date
 - Type of document
 - Status of document (new, amendment)
- Intended to anticipate the eCTD



Sample CDER CTOC eIND model

Electronic Regulatory Submission a	nd Revie	w (ERSR) - I	Microsoft Internet	Explorer						_	8 × 🗄
<u>File Edit View Favorites Tools Help</u>											
← → → Ø D Back Forward Stop Refresh	n Home	Q Search F	avorites History	Mail Print	Edit						nks »
Address 🛃 file:///C:/v500/Resource/Tool.	/Main_v50	0.htm#admin=0	:/v500/ind_60999/0	002/					-	∂Go Li	
GDEP					Clinical						
ERSR SYSTEM								ŝ	⇒ 🔨 🕺	🗗 i	?
Table of Contents						~~					
Module: Clinical					IND: 609	100000					
Record: Current					SB-2710						
✓ Clinical (IND 60999)					GlaxoSmith						
✓ Reports of Bioavailability and Bioavailability and				App	roval Date:	pending					
Bioequivalence Studies											
BA Protocol 003			Submissio	in				Module			
BA Protocol 003 Amendment	Туре	Sequence	Serial Number	Date	Filing	Regional	Summaries	Quality	Nonclinical	Clinical	
Protocol 003 Investigator	-		0002	2000-10-24	amendment	X			X		
Information	I		0001	2000-10-06	amendment	X				X	
	1		0000	2000-09-27	original	X	X	×	X	×	
											T
Search										22	× .
🍯 Done 🏽 🔀 Start 🛛 🙆 Michael J Brennan - 2 GB	[PB] Miner	soft PowerPoin		a atao		ation Informati	m lairt-t		My Con	nputer	
Start Wichael J Brennan - 2 GB	Cal Micro	son FowerPoin	it - [DI	iy - ctoc		ation Informati	on	onic Regi	natory		A 15:4



Module 1 Organization (July 2001)

m1-1-table-of-contents	
m1-2-reports-documents- summaries	m1-2-1-introductory-statement m1-2-2-financial-disclosure m1-2-3-letters-of-authorization m1-2-4-patents m1-2-5-postmarketing-commitments m1-2-6-user-fee m1-2-7-cover-letters m1-2-7-cover-letters m1-2-8-waivers
m1-3-prescribing-certifications	m1-3-1-Field copy m1-3-2-debarment
m1-4-forms	Form 356h, Form 1571
m1-5-labeling	m1-5-1-viewing-graphic m1-5-1-1-final m1-5-1-2-draft m1-5-1-2-text
m1-6-other	Risk Management, Foreign Marketing History, etesk GlaxoSmithKline

Module 1 (Jan 2003)

M1-1 Forms	1571, 356h, 2252, 2253, 3397, 3316,3331
M1-2	Cover Letter
M1-3 Administrative Information	1-3-1 applicant-information , 1-3-2 field-copy-certification, 1-3-3debarment-certification, 1-3-4 financial-certification- disclosure, 1-3-5 patent-exclusivity
m1-4-references	m1-4-1-letter-authorization, m1-4-2-statement-right- reference, m1-4-3-list-of-authorized-persons-to- incorporate-by-reference, m1-4-4-cross-reference-other- applications
m1-5-application-status	m1-5-1-withdrawal-request , m1-5-2-inactivation-request , m1-5-3-reactivation-request , m1-5-4-reinstatement-request , m1-5-5-withdrawal-unapproved-nda , m1-5-6-withdrawal-of-listed-drug , m1-5-7-request-withdrawal-application-approval
m1-6-meetings	m1-6-1-meeting-request, m1-6-2-meeting-background- materials, m1-6-3-correspondence-regarding-meetings



Module 1 (Jan 2003) cont

m1-7-fast-track	m1-7-1-fast-track-designation-request, m1-7-2-fast- track-designation-withdrawal-request, m1-7-3- rolling-review-request
m1-8-special-protocol- assessment-request	m1-8-1-clinical-study , m1-8-2-carcinogenicity-study , m1-8-3-stability-study
m1-9-pediatric- administrative-information	m1-9-1-request-waiver-pediatric-studies , m1-9-2- request-deferral-pediatric-studies , m1-9-3-request- pediatric-exclusivity-determination , m1-9-4- proposed-pediatric-study-request-amendments , m1- 9-5-proposal-written-agreement , m1-9-6-other- correspondence-regarding-pediatric-exclusivity- study-plans
m1-10-dispute-resolution	m1-10-1-request-for-dispute-resolution, m1-10-2- correspondence-related-to-dispute-resolution



Module 1 (Jan 2003) Cont

m1-12-othercorrespondence

m1-12-1-pre-ind-correspondence, m1-12-2-requestcharge, m1-12-3-notification-charging-undertreatment-ind, m1-12-4-request-comments-advice-ind , m1-12-5-request-waiver , m1-12-6-exemptioninformed-consent-emergency-research, m1-12-7public-disclosure-statement-emergency-care-research , m1-12-8-correspondence-regarding-emergencycare-research, m1-12-9-notification-discontinuationclinical-trial, m1-12-10-generic-drug-enforcement-actstatement, m1-12-11-basis-submission-statement, m1-12-12-comparison-generic-drug-reference-listeddrug, m1-12-13-request-waiver-vivo-studies, m1-12-14-request-for-comments-for-promotional-material, m1-12-15-environmental-analysis, m1-12-16-requestwaiver-vivo-bioavailability-studies, m1-12-17-fieldalert-reports, m1-12-18-risk-management-plans



Module 1 (Jan 2003) Cont

m1-13-annual-report	m1-13-1-summary-nonclinical-studies , m1-13-2- summary-clinical-pharmacology-information , m1- 13-3-summary-safety-information , m1-13-4- summary-labeling-changes , m1-13-5-summary- other-significant-new-information , m1-13-6- individual-study-information , m1-13-7-general- investigational-plan , m1-13-8-foreign-marketing- history , m1-13-9-distribution-data , m1-13-10- status-postmarketing-study-commitments , m1- 13-11-status-other-postmarketing-studies , m1- 13-12-log-outstanding-regulatory-business
m1-14-labeling	m1-14-1-draft-labeling, m1-14-2-final-labeling, m1-14-3-listed-drug-labeling, m1-14-4- investigational-drug-labeling, m1-14-5-foreign- labeling



Questions as we look ahead

- How will a transition to an "e-cumulative" model impact in-licensing decisions?
 - Documentation completeness and standards needs to be addressed upfront rather than waiting for surprises
 - Who within the organization should be making this assessment?



Questions as we look ahead

- Do we have the right organizations in place to respond to the challenges of fully electronic submissions?
 - What expectations need to be set for document authors?
 - Can Regulatory Affairs be a passive observer in the transition to fully electronic submissions?
 - Do we defer all decisions about hypertext linking to electronic document publishers?



Summary

- Where are we now? Agreed specifications and and robust viewer (in the wings?)
- Need to look beyond this transition as solely a technology problem – Can we convince reviewers (and sponsor staff) that the eCTD is the way to go?
- Can we build the business case around major marketing applications (NDA, BLA, NDS) or should we look to more dynamic transactional submissions to highlight the benefits of the eCTD?

